Leveraging Adeno-Associated Viruses (AAVs) in therapeutic approaches for monogenic neurological diseases
Supplied by PerkinElmer on Wednesday, 07 September, 2022
Within the field of neurological diseases, there is great interest in looking at rare diseases of monogenic origin with the hope of developing disease-modifying gene therapies, as opposed to treatments for symptom management. Therefore, using relatively tunable systems like recombinant AAVs, scientists are also exploring in vivo gene delivery in parallel to ex vivo.
Learn about key strategies and innovations in this space that are enabling advanced gene therapy.
Related White Papers
Continuous environmental monitoring — compliance and best practice tips
Automated environmental monitoring systems are now a critical element in many laboratory...
Leading pharma company delivers next-level quality and compliance — a case study
Discover how to easily monitor multiple...
Your guide to cell-based fluorescence assays
Learn how to master the challenges of cell-based fluorescence assays and improve the quality and...
